文献速递淋巴瘤

检查点抑制剂联合奥妥珠单抗及PET适应超低剂量淋巴结放疗在初治滤泡性淋巴瘤中显示高效:II期FLUORO研究结果

Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.
PubMed 文献 · Br J Haematol · 2026-04-08

完全缓解率达93%,客观缓解率100%,3年无进展生存率80%,总生存率100%,3-4级不良事件发生率31%。

要点

  • 初治高肿瘤负荷FL中CR率93%、ORR 100%,3年PFS 80%、OS 100%。
  • 3-4级不良事件发生率31%,其中2例为免疫相关不良事件。
  • 该无化疗多模式方案显示 promising 疗效与安全性,值得进一步研究。

核心结论

  • 奥妥珠单抗、阿替利珠单抗联合超低剂量淋巴结放疗在初治FL中具有 promising 疗效和安全性,提供潜在的无化疗新选择。

研究设计与样本

  • 中位年龄53岁,94%患者FLIPI评分为中/高危。
  • 治疗方案:阿替利珠单抗联合奥妥珠单抗6周期,第2周期后对PET阳性部位行4Gy超低剂量放疗,继以奥妥珠单抗维持2年。

主要发现

  • 完全缓解率93%(95%CI 70%-99%),客观缓解率100%(95%CI 75%-100%)。
  • 中位随访41个月,3年无进展生存率80%(95%CI 55-93),总生存率100%(95%CI 79.6-100)。
  • 3-4级不良事件发生率31%,其中2例为免疫相关不良事件。
  • 基线PET影像组学和免疫转录组学特征提示可能作为免疫治疗反应的预测标志物。

临床怎么用

  • 该无化疗方案可能适用于初治高肿瘤负荷FL患者,尤其需避免化疗毒性者。
  • PET适应超低剂量放疗(4Gy)可作为免疫治疗的增效手段。
  • 治疗前PET影像组学和免疫转录组学或有助于预测免疫治疗反应。

局限性

  • 随访时间有限(中位41个月),长期疗效和安全性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma (FL) first-line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment-naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)-adapted ultra-low dose radiotherapy (RT; 4Gy) to all PET-avid sites after cycle 2, followed by 2 years of obinutuzumab maintenance. Sixteen eligible patients were enrolled (15 evaluable for response) to our Phase II trial (NCT04962126). Median age was 53 years with 94% intermediate/high Follicular Lymphoma International Prognostic Index (FLIPI) score. The primary end-point of complete response (CR) was achieved in 93% (95% confidence interval [CI]: 70%-99%) with objective response rate (ORR) of 100% (95% CI: 75%-100%). With 41-month median follow-up, 3-year progression-free survival (PFS) was 80% (95% CI: 55-93) and OS was 100% (95% CI: 79.6-100). Grade 3-4 adverse events occurred in 31% of patients (2 immune-related). Baseline PET radiomics and immune transcriptomics demonstrated profiles suggesting promise as predictive markers of immunotherapy response, consistent with our prior findings. The novel multimodality combination of obinutuzumab, atezolizumab and ultra-low dose nodal RT in treatment-naïve FL has promising efficacy and safety, offering a potential novel chemo-free option. Further studies using low-cost RT to augment immunotherapy are warranted. This trial was registered in clinicaltrials.gov, registration number: NCT04962126.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Martynchyk A, Chong G, Khor R, et al. Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study. Br J Haematol. 2026. PMID: 41949430. doi:10.1111/bjh.70468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。